Otsuka Pharmaceutical and H. Lundbeck have announced marketing authorization approval from the European Commission for Abilify Maintena (aripiprazole), an intramuscular (IM) once-monthly injectable formulation for maintenance treatment of ...
H Lundbeck has expanded its current alliance with Otsuka Pharmaceutical (Otsuka) to include development and commercialization of nalmefene in Japan. Earlier in 2013, nalmefene was approved by the European Medicines Agency (EMA) as the ...
Tags: Lundbeck, Otsuka Pharmaceutical
Lundbeck, a Denmark-based pharmaceutical company, has obtained the US Food and Drug Administration (FDA) approval for its SABRIL (vigabatrin), an adjunctive treatment option for children 10 and older with refractory complex partial ...
Danish pharmaceutical company H. Lundbeck and Japanese drugmaker Otsuka Pharmaceutical have announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended marketing approval for ...
Danish drugmaker Lundbeck has announced the availability of ONFI (clobazam) in scored tablet and oral suspension formulations in the US pharmacies beginning this week. ONFI, an oral anti-epileptic drug (AED) of the benzodiazepine class, ...
Denmark-based pharmaceutical company H. Lundbeck has announced plans to enhance and simplify its commercial structure in Europe to boost its ability to launch new medicines. As per the plan, the project could result in elimination of up ...
Tags: Lundbeck, Europe, Health&Medicine
The European Commission (EC) has imposed a fine of €146m on nine pharma companies, including Ranbaxy Laboratories, for blocking the entry of cheaper generic drug of Lundbeck's anti-depressant, citalopram. Lundbeck agreed with each of ...
Tags: Ranbaxy, Halting Generic Drugs
The European Union (EU) is expected to penalize nine companies, including Denmark-based Lundbeck and Indian firm Ranbaxy for halting generic medicines from entering into the market and violating competition laws. Other companies scheduled ...
Tags: Drug Firms, Drugs'Entry
H. Lundbeck has introduced the first approved medication reducing alcohol consumption in alcohol dependent patients in Norway, Finland, Poland and the Baltic markets. Additional launches in other European countries are expected to follow ...
Tags: Lundbeck, Baltic Markets
Genmab has achieved a third pre-clinical milestone that generates a payment worth €1m as part of a collaboration with Lundbeck. The deal allows Genmab, which received €7.5m upfront payment previously, to develop human ...
Tags: Genmab, clinical trial, cooperation
Takeda Global Research & Development Center and Lundbeck have announced the FDA acceptance of vortioxetine new drug application (NDA) filing for major depressive disorder. The companies have also announced the proposal of Brintellix as ...
Tags: FDA, new drug application, NDA
Takeda Pharmaceutical Company and H. Lundbeck have submitted a new drug application (NDA) to the FDA for vortioxetine (Lu AA21004), an investigational drug for the treatment of major depressive disorder (MDD). Vortioxetine is under ...
Tags: Takeda Pharmaceutical Company, major depressive disorder, MDD